Trem1 - triggering receptor expressed on myeloid cells 1 Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 301229

Summary

Predicted to enable scaffold protein binding activity. Involved in several processes, including cellular response to lipid; positive regulation of cardiac muscle cell apoptotic process; and positive regulation of macrophage chemotaxis. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. Used to study several diseases, including acute pancreatitis; Bacterial sepsis; mesenteric vascular occlusion; middle cerebral artery infarction; and pleural empyema. Biomarker of congestive heart failure; mental depression; periodontitis; and rheumatoid arthritis. Human ortholog(s) of this gene implicated in Bacterial sepsis and malaria. Orthologous to human TREM1 (triggering receptor expressed on myeloid cells 1). [provided by Alliance of Genome Resources, Apr 2022]

Trem1 Products (1)

mRNA Protein Name
NM_001106885.1 NP_001100355.1 triggering receptor expressed on myeloid cells 1

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
involved in cellular response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
26383906 RGD
involved in cellular response to vitamin D IEP
IEP: Inferred from expression pattern
29331667 RGD
involved in positive regulation of cell-matrix adhesion IDA
IDA: Inferred from direct assay
29331667 RGD
involved in positive regulation of cell-matrix adhesion IMP
IMP: Inferred from mutant phenotype
29331667 RGD
involved in positive regulation of macrophage chemotaxis IDA
IDA: Inferred from direct assay
29331667 RGD
involved in positive regulation of macrophage chemotaxis IMP
IMP: Inferred from mutant phenotype
29331667 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

triggering receptor expressed on myeloid cells 1

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-P3211A Nangibotide TFA Inhibitor 99.86% Phase 2
HY-P3211 Nangibotide Inhibitor 98.53% Phase 2
Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P990650 PY159 Inhibitor 98.44% Phase 1

Pre-clinical Phase

Bioactive Molecules (10)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-157122 VJDT Inhibitor 99.68% Unkown
HY-174369 TREM2 agonist-3 99.39% Unkown
HY-P10086 TREM-1 inhibitory peptide GF9 Inhibitor 99.41% Unkown
HY-P11077 LR-17 Inhibitor 97.52% Unkown
HY-182702 As48 / Unkown
HY-P10938 LP17 (human) Inhibitor 90.14% Unkown
HY-RS15002 TREM1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS16560 Trem1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-P10088 Mouse TREM-1 SCHOOL peptide, control Control / Unkown
HY-RS22992 Trem1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Trem1 NCBI NCBI:54210